Tumors are able to form with no DNA mutations, fly study shows

CPRIT awards over $60M in grants

The Cancer Prevention and Research Institute of Texas approved $60.6 million in grants.

September 13, 2024

Immunological features predict treatment response for advanced solid tumors

The AMADEUS clinical trial sheds light on how biomarkers can predict how patients respond to immune checkpoint inhibitor treatments like nivolumab and ipilimumab.

September 13, 2024

Vol.50 No.34

In Brief

Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor

Laurie H. GlimcherBenjamin Levine EbertLaurie H. Glimcher will step down as Dana-Farber Cancer Institute president and CEO on Oct. 1.

September 06, 2024

Vol.50 No.33

Clinical Roundup

Misetionamide shows promising antitumor effects in ovarian cancer, preclinical study shows

Misetionamide, a tumor cell-selective small molecule drug that is broadly active in multiple cancer models, demonstrated excellent monotherapy results as well as synergistic activity with PARP inhibitors and bevacizumab antineoplastic in ovarian cancer in a recent preclinical study.

September 06, 2024

Vol.50 No.33

In Brief

MD Anderson and industry partners to conduct T cell studies on the International Space Station

The University of Texas MD Anderson Cancer Center and collaborators are initiating a research project that will send T cells to the International Space Station to study the effects of prolonged microgravity on cell differentiation, activation, memory, and exhaustion.

August 02, 2024

Vol.50 No.31